Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study.

Delgado V, Biermasz NR, van Thiel SW, Ewe SH, Marsan NA, Holman ER, Feelders RA, Smit JW, Bax JJ, Pereira AM.

Clin Endocrinol (Oxf). 2012 Jul;77(1):99-105. doi: 10.1111/j.1365-2265.2011.04326.x.

PMID:
22211510
2.

Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.

Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM.

J Clin Endocrinol Metab. 2008 Sep;93(9):3348-56. doi: 10.1210/jc.2007-2658. Epub 2008 Jun 17.

PMID:
18559921
3.

Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.

Auriemma RS, Pivonello R, Perone Y, Grasso LF, Ferreri L, Simeoli C, Iacuaniello D, Gasperi M, Colao A.

Eur J Endocrinol. 2013 Aug 28;169(3):359-66. doi: 10.1530/EJE-13-0231. Print 2013 Sep.

4.

Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.

Elenkova A, Shabani R, Kalinov K, Zacharieva S.

Eur J Endocrinol. 2012 Jul;167(1):17-25. doi: 10.1530/EJE-12-0121. Epub 2012 Apr 16.

5.

Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study.

Nachtigall LB, Valassi E, Lo J, McCarty D, Passeri J, Biller BM, Miller KK, Utz A, Grinspoon S, Lawson EA, Klibanski A.

Clin Endocrinol (Oxf). 2010 Jan;72(1):53-8. doi: 10.1111/j.1365-2265.2009.03608.x. Epub 2009 Apr 17.

PMID:
19508591
6.

Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.

Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA.

Clin Endocrinol (Oxf). 2009 Jan;70(1):104-8. doi: 10.1111/j.1365-2265.2008.03458.x.

PMID:
19128367
7.

Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required.

Kars M, Pereira AM, Bax JJ, Romijn JA.

Eur J Endocrinol. 2008 Oct;159(4):363-7. doi: 10.1530/EJE-08-0611. Epub 2008 Aug 14. Review.

8.

Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas.

Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G, Serri O.

Pituitary. 2009;12(3):153-7. doi: 10.1007/s11102-008-0134-2.

PMID:
18594989
9.

Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.

Yarman S, Kurtulmus N, Bilge A.

Neuro Endocrinol Lett. 2012;33(3):340-6.

PMID:
22635095
10.

[Cabergoline in hyperprolactinemia and valvular heart disease].

Vargas ML, Cervantes CE, Hernando CA, Da Costa CV.

Endocrinol Nutr. 2009 Oct;56(8):412-7. doi: 10.1016/S1575-0922(09)72711-1. Review. Spanish.

PMID:
19959151
11.

The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data.

Caputo C, Prior D, Inder WJ.

Lancet Diabetes Endocrinol. 2015 Nov;3(11):906-13. doi: 10.1016/S2213-8587(14)70212-8. Epub 2014 Nov 14. Review. Erratum in: Lancet Diabetes Endocrinol. 2015 Nov;3(11):e10.

PMID:
25466526
12.

Transforming growth factor β1 is not a reliable biomarker for valvular fibrosis but could be a potential serum marker for invasiveness of prolactinomas (pilot study).

Elenkova A, Atanassova I, Kirilov G, Vasilev V, Kalinov K, Zacharieva S.

Eur J Endocrinol. 2013 Jul 29;169(3):299-306. doi: 10.1530/EJE-13-0081. Print 2013 Sep.

13.

Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?

Vallette S, Serri K, Serri O.

Expert Rev Cardiovasc Ther. 2010 Jan;8(1):49-54. doi: 10.1586/erc.09.167.

PMID:
20014934
14.

Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias?

Gu H, Luck S, Carroll PV, Powrie J, Chambers J.

Clin Endocrinol (Oxf). 2011 May;74(5):608-10. doi: 10.1111/j.1365-2265.2010.03973.x.

PMID:
21198745
15.

Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.

De Vecchis R, Esposito C, Ariano C.

Herz. 2013 Dec;38(8):868-80. doi: 10.1007/s00059-013-3816-0. Epub 2013 Jun 8. Review.

PMID:
23743769
16.

Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G.

N Engl J Med. 2007 Jan 4;356(1):39-46.

17.

A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas.

Boguszewski CL, dos Santos CM, Sakamoto KS, Marini LC, de Souza AM, Azevedo M.

Pituitary. 2012 Mar;15(1):44-9. doi: 10.1007/s11102-011-0339-7.

PMID:
21847572
18.

Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.

Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G.

J Clin Endocrinol Metab. 2008 Oct;93(10):3777-84. doi: 10.1210/jc.2007-1403. Epub 2008 Aug 5.

PMID:
18682513
19.

Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.

Tan T, Cabrita IZ, Hensman D, Grogono J, Dhillo WS, Baynes KC, Eliahoo J, Meeran K, Robinson S, Nihoyannopoulos P, Martin NM.

Clin Endocrinol (Oxf). 2010 Sep;73(3):369-74. doi: 10.1111/j.1365-2265.2010.03827.x. Epub 2010 Jun 9.

PMID:
20550538
20.

Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.

Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G.

Cardiovasc Ther. 2011 Dec;29(6):404-10. doi: 10.1111/j.1755-5922.2010.00169.x. Epub 2010 Jun 11.

PMID:
20553285

Supplemental Content

Support Center